Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
87 search results for:

Metastatic melanoma 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. play
    05-04-2018 | Uveal melanoma | Podcast | Video

    SUMIT: Selumetinib in metastatic uveal melanoma

    This edition of the medwireNews podcast focuses on a recent trial of the MEK inhibitor selumetinib in metastatic uveal melanoma. Advisory Board member and study author Paul Nathan outlines the findings and discusses the wider implications.

  2. 05-04-2018 | Teaser

    SUMIT: Selumetinib in metastatic uveal melanoma

    This edition of the medwireNews podcast focuses on a recent trial of the MEK inhibitor selumetinib in metastatic uveal melanoma. Advisory Board member and study author Paul Nathan outlines the findings and discusses the wider implications.

  3. 07-09-2018 | Metastatic melanoma | News | Article

    FDG-PET predicts metastatic melanoma outcomes better than CT imaging

    Using 18 F-fluorodeoxyglucose–positron emission tomography to measure treatment response at 1 year in patients with metastatic melanoma may better predict long-term outcomes than standard computed tomography, research shows.

    Published in:
    Ann Oncol 2018; doi:10.1093/annonc/mdy330
  4. 20-08-2018 | Metastatic melanoma | Article

    Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma

    Auslander N et al. Nat Med 2018; 24: 1545–1549.

  5. 14-05-2019 | Quality of life | Article

    An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors

    O’Reilly A et al. Support Care Cancer 2020; 28: 561. doi:10.1007/s00520-019-04818-w

  6. 04-08-2017 | Melanoma | News | Article
    News in brief

    Concurrent multisite radiotherapy, immunotherapy shows metastatic melanoma potential

    Early results suggest that combining multisite radiotherapy with immune checkpoint inhibitor therapy can lead to positive outcomes in patients with metastatic melanoma without adding to the toxicity burden.

  7. 14-09-2017 | Melanoma | ESMO 2017 | Article
    ESMO 2017

    Adjuvant nivolumab improves RFS over ipilimumab in metastatic melanoma patients

    Patients with resected stage IIIB–IV melanoma derive a significant recurrence-free survival benefit from adjuvant treatment with nivolumab versus ipilimumab, interim results from the CheckMate 238 trial indicate.

    Published in:
    N Engl J Med 2017; Advance online publication
  8. 13-06-2017 | Melanoma | Conference coverage | Article
    ASCO 2017

    Nivolumab, ipilimumab duo elicits durable intracranial metastatic melanoma response

    Patients with melanoma and untreated, asymptomatic brain metastases benefit from treatment with a combination of nivolumab and ipilimumab, suggest the results of the ABC and CheckMate 204 trials.

    Published in:
    J Clin Oncol 2017; 35 : 9507, 9508
  9. 17-08-2017 | Melanoma | Article

    Metastatic melanoma: prognostic factors and survival in patients with brain metastases

    This retrospective study assesses the viability of the melanoma-specific graded prognostic assessment in modern populations, with the aim of determining the efficacy of stereotactic radiosurgery combined with other systemic therapies versus whole-brain radiotherapy. Frinton E et al.  J Neurooncol 2017. doi:10.1007/s11060-017-2591-9

  10. 27-02-2017 | Cutaneous melanoma | News | Article

    Immunotherapy trial eligibility criteria exclude majority of metastatic melanoma patients

    Over half of patients with metastatic melanoma do not meet eligibility criteria for participation in phase III clinical trials of immunotherapy agents, highlight study findings.

    Published in:
    Eur J Cancer 2017; 74 : 89–95
  11. 30-09-2017 | Metastatic melanoma | Article

    Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study

    Chapman PB et al.  Ann Oncol  2017; 28(10): 2581-2587. doi:10.1093/annonc/mdx339

  12. 25-05-2023 | Checkpoint blockade | News | Article

    Real-world data provide reassurance for ICI use in people with HIV and cancer

    The investigators also compared the outcomes of 61 PWH with those of 110 matched participants without HIV, all of whom received ICIs for metastatic NSCLC.

    Author:
    Shreeya Nanda
    Published in:
    J Clin Oncol 2023; doi:10.1200/JCO.22.02459
  13. 20-01-2023 | Immunotherapy | News | Article

    IL-7 genetic variant linked to ICI toxicity

    For the second study, Benjamin Fairfax (University of Oxford, UK) and co-workers drew on the Oxford Radcliffe Biobank to identify 214 patients who received ICIs for melanoma, either in the metastatic or adjuvant setting, between 2015 and 2021.

    Author:
    Shreeya Nanda
    Published in:
    Nat Med 2022; 28 : 2584–2591 Nat Med 2022; 28 : 2592–2600 Nat Med 2022; 28 : 2471–2472
  14. 13-07-2022 | Immunotherapy | News | Article

    ICI therapy feasible in advanced cancer patients with kidney transplant using immunosuppression

    Their phase 1 study included 17 patients with incurable, locally advanced or metastatic tumors, namely cutaneous cell carcinoma (35%) or squamous cell carcinoma (18%) of the head and neck, cancers of the kidney (12%), liver (6%), lung (6%), or colon (6%), Merkel cell carcinoma (12%), or melanoma (6%) from three Australian hospitals.

    Author:
    Lynda Williams
    Published in:
    Lancet Oncol 2022; doi: 10.1016/S1470-2045(22)00368-0 Lancet Oncol 2022; doi: 10.1016/S1470-2045(22)00395-3
  15. 07-07-2022 | Genetics | News | Article

    Electronic health data picks up cancer gene–treatment interactions

    For metastatic breast cancer, RB1 and CCND1 mutations were associated with improved survival during chemotherapy (HRs=0.74 and 0.73, respectively), which Zou et al say is also in line with previous findings.

    Author:
    Laura Cowen
    Published in:
    Nat Med 2022; doi:10.1038/s41591-022-01873-5
  16. 09-04-2022 | Immunotherapy | Adis Journal Club | Article
    BioDrugs

    Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing

    DOI [Teaser] Key Points The treatment of advanced (metastatic stage IV) melanoma with systemic (immuno)therapies has significantly improved survival.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.